Read More Pharma Industry News Why pancreatic cancer clinicians and investors are closely watching AIM ImmunoTech’s next move AIM ImmunoTech’s next Ampligen move could reshape pancreatic cancer treatment and investor sentiment. Find out what executives and markets are watching now. bySoujanya RaviApril 19, 2026